Literature DB >> 2658099

Introduction and overview of hematopoietic growth factors.

J L Gabrilove1.   

Abstract

Blood cell development is regulated by a variety of hematopoietic growth factors that mediate the growth, maturation, and activation of hematopoietic cell elements. Several of these factors have been isolated and are now being produced by means of recombinant DNA techniques in quantities sufficient for study and clinical use. Three factors in particular have recently received considerable attention in the clinical arena: recombinant human granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage colony-stimulating factor (GM-CSF), and erythropoietin (EPO). Although both may prove to be clinically useful, G-CSF and GM-CSF have distinct and different biological characteristics. The regulatory action of G-CSF is apparently lineage-specific for the proliferation and maturation of neutrophil granulocytes. GM-CSF is less restricted in its actions, affecting all granulocytes, especially eosinophil granulocytes. It also stimulates the proliferation and activation of monocyte-macrophages and induces these cells to produce a number of cytokines. EPO mediates the growth of erythroid progenitors into mature erythrocytes. The CSFs and EPO have many potential clinical applications, including enhancing myeloid effector cell production and function, rendering malignant cells more susceptible to killing by cycle-specific agents, and correcting the anemia of end-stage renal disease.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2658099

Source DB:  PubMed          Journal:  Semin Hematol        ISSN: 0037-1963            Impact factor:   3.851


  7 in total

Review 1.  G-CSF: status quo and new indications.

Authors:  F Herrmann
Journal:  Infection       Date:  1992 Jul-Aug       Impact factor: 3.553

2.  Thermal injury increases the number of eosinophil progenitors in rat spleen and bone marrow.

Authors:  J G Noel; D A Wells; X Guo; F Kong; G J Lovell; C K Ogle
Journal:  Inflammation       Date:  2001-10       Impact factor: 4.092

3.  Recombinant granulocyte colony-stimulating factor (rG-CSF): pharmacoeconomic considerations in chemotherapy-induced neutropenia.

Authors:  D Faulds; N J Lewis; R J Milne
Journal:  Pharmacoeconomics       Date:  1992-04       Impact factor: 4.981

Review 4.  Colony-stimulating factors. Present status and future potential.

Authors:  R M Fox
Journal:  Pharmacoeconomics       Date:  1994       Impact factor: 4.981

5.  Hematologic effects of recombinant murine granulocyte-macrophage colony-stimulating factor on the peripheral blood and bone marrow.

Authors:  T R Ulich; J del Castillo; I McNiece; L Watson; S M Yin; J Andresen
Journal:  Am J Pathol       Date:  1990-08       Impact factor: 4.307

Review 6.  Recombinant granulocyte colony-stimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions.

Authors:  L M Hollingshead; K L Goa
Journal:  Drugs       Date:  1991-08       Impact factor: 9.546

7.  IMPACT OF PROPHYLACTIC USE OF COLONY STIMULATING FACTORS ON THE PATTERN OF NEUTROPENIA AND INFECTIONS IN MODERATELY INTENSIVE CHEMOTHERAPY.

Authors:  R Ranga Rao; Y S Sarma; R K Gupta; R K Malik
Journal:  Med J Armed Forces India       Date:  2017-06-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.